Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.67 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.67 |
| ▸ | GRM5 | P41594 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3719278 | 0.99 | CHRNB2 (0.66) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL2120828 | 0.86 | CHRNB2 (0.67) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL2118901 | 0.86 | GRM5 (0.59) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL2122956 | 0.81 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL2120622 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL2120756 | 0.76 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL1847996 | 0.76 | GRM5 (0.60) | GRM5MAPT | |
| SCHEMBL2040551 | 0.76 | CHRNB2 (0.72) | CHRNB2CHRNA5CHRNA4GRM5NPC1 | |
| SCHEMBL4699227 | 0.75 | GRM5 (0.74) | CHRNB2CHRNA5CHRNA4GRM5 | |
| SCHEMBL4699177 | 0.75 | GRM5 (0.67) | CHRNB2CHRNA5CHRNA4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095056-A1 | 2,5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-04-19 | — | — | US | claimed |
| WO-2010106106-A1 | 2, 5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2010-09-23 | — | — | WO | claimed |
| US-20120095056-A1 | 2,5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| WO-2010106106-A1 | 2, 5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095056-A1 | 2,5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA5, CHRNA2, CHRNA7 | CHRNB2 8/4885CHRNA5 1/4885CHRNA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.